We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 28, 2019

Symptoms, Function, and Qualify of Life in the DAPA-HF Trial



Additional Info

Disclosure statements are available on the authors' profiles:

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Circulation 2019 Nov 17;[EPub Ahead of Print], MN Kosiborod, P Jhund, KF Docherty, M Diez, MC Petrie, S Verma, JC Nicolau, B Merkely, M Kitakaze, DL DeMets, SE Inzucchi, L Køeber, FA Martinez, P Ponikowski, MS Sabatine, SD Solomon, O Bengtsson, D Lindholm, A Niklasson, M Sjöstrand, AM Langkilde, JJV McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading